BioCentury
ARTICLE | Clinical News

ImmuDyn immune modulatory lipid preparation data

July 28, 1997 7:00 AM UTC

In a Phase I/II trial in India, 8 HIV-infected patients were given intramuscular injections of 0.5 mg ImmuDyn weekly for 18 weeks and observed for an additional 14 weeks. A decrease in viral load was observed in 5 of the patients within 3 weeks. Virus levels increased as treatment continued, but did not rise above baseline. Overall increases in CD4+ T cell counts also were observed by the end of the study. No new opportunistic infections developed with ImmuDyn treatment, and patient body weight increased by an average of 3 kg. ...